KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Edwards Lifesciences (EW) EPS (Weighted Average and Diluted) (2016 - 2026)

Edwards Lifesciences has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at $0.11 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 83.08% year-over-year to $0.11; the TTM value through Dec 2025 reached $1.79, down 74.17%, while the annual FY2025 figure was $1.81, 22.65% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.11 at Edwards Lifesciences, down from $0.5 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $5.13 in Q3 2024 and troughed at $0.11 in Q4 2025.
  • A 5-year average of $0.77 and a median of $0.56 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 714.29% in 2024 and later crashed 90.25% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.53 in 2021, then tumbled by 37.74% to $0.33 in 2022, then skyrocketed by 66.67% to $0.55 in 2023, then grew by 18.18% to $0.65 in 2024, then crashed by 83.08% to $0.11 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for EW at $0.11 in Q4 2025, $0.5 in Q3 2025, and $0.57 in Q2 2025.